For instance, while directed analysis has revealed CRIPTO to be a stem cell regulatory factor that is frequently re-emergent in diverse cancers and concordantly shown it to be a clinically relevant biomarker of disease progression, unsupervised studies rarely identify CRIPTO and it remains difficult to detect in many settings where its ablation and blockade show significant effects (authors’ collective observations). This evidence concerns the gene CRIPTO and cancer.